Article
Surge in ADC Deals Drives Oncology Dealmaking
IQVIA Pharma Deals
Sep 19, 2024
Download
In recent years, antibody-drug conjugates (ADCs) have increasingly become more prominent in dealmaking in the life sciences sector, as leading industry players look to gain access to the transformative drug modalities. Notably, there was a marked increase in ADC deal volume from 2022 to 2023, with ADCs being the key drivers of several high-profile deals, particularly focused on oncology indications in the discovery and preclinical phases of development.  

Read this to understand how antibody-drug conjugates (ADCs) are driving high-profile transactions in life sciences, particularly in oncology. Explore the surge in ADC deals from 2019 to the first half of 2024, and discover the innovative technologies revitalizing this therapeutic class. The article also delves into early-stage partnerships, key M&A and partnering deals, and provides an outlook on the future of ADCs in the industry. 

Download the article to uncover more.

Related solutions

Contact Us